ArriVent BioPharma Inc

NASDAQ: AVBP
$17.70
-$0.29 (-1.6%)
Closing price May 10, 2024

AVBP Chart and Intraday Price

AVBP Company Data

Asset Type Stock
Exchange NASDAQ
Currency USD
Country USA
Sector TECHNOLOGY
Industry GENERAL
Address NONE
Fiscal Year End September
Latest Quarter None
Market Cap 0.00M USD
ArriVent BioPharma, Inc. is a clinical-stage biopharmaceutical company focused on creating innovative medicines for cancer patients with critical needs. It specializes in developing targeted therapies, particularly for non-small-cell lung cancer (NSCLC) and other solid tumors. Among its key projects is Furmonertinib, a promising drug in phase 3 trials aimed at NSCLC. Founded in 2021 and headquartered in Newtown Square, Pennsylvania, ArriVent BioPharma is also known for its strategic partnership with Aarvik Therapeutics Inc., enhancing its development capabilities.

AVBP Articles

Insider Buying at These Biotechs Is Huge
As January wound to a close, beneficial owners, executives, and other insiders took advantage of public offerings of stock at these biotech companies.
Trey Thoelcke
Published: